Jade biosciences completes closing of merger with aerovate therapeutics and previously announced private placement of approximately $300 million

Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases lead candidate jade-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 the combined company will operate as “jade biosciences, inc.” and will trade on nasdaq under the ticker symbol “jbio” san francisco and vancouver, british columbia, april 28, 2025 (globe newswire) -- jade biosciences, inc. (“jade” or the “company”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with aerovate therapeutics, inc. (“aerovate”). the combined company will operate as jade biosciences, inc., with its shares expected to begin trading on the nasdaq capital market on april 29, 2025, under the ticker symbol “jbio.
NDAQ Ratings Summary
NDAQ Quant Ranking